Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Laura E. Baldassari"'
Autor:
Laura E. Baldassari, Jeffrey A. Cohen
Publikováno v:
EBioMedicine, Vol 29, Iss , Pp 5-6 (2018)
Externí odkaz:
https://doaj.org/article/1958ac28242f408bad6a34aa163f9e03
Autor:
Kenneth Earl Sakaie, Jeffrey A. Cohen, Yanming Wang, Paul J. Tesar, Jenny Feng, Se-Hong Oh, Laura E. Baldassari, Benjamin L.L. Clayton
Publikováno v:
Expert Review of Neurotherapeutics. 19:997-1013
Introduction: Approved disease-modifying therapies for multiple sclerosis (MS) lessen inflammatory disease activity that causes relapses and MRI lesions. However, chronic inflammation and demyelination lead to axonal degeneration and neuronal loss, f
Autor:
Robert Lowsky, Paolo A. Muraro, Richard A. Nash, Laura E. Baldassari, Stefanie Sarantopoulos, Mark S. Freedman, James Bowen, Marcelo C. Pasquini, Paul A. Carpenter, Keith M. Sullivan, Christopher Bredeson, Jan Storek, Bipin N. Savani, John R. Corboy, Linda M. Griffith, Harold L. Atkins, Jeffrey A. Cohen, George E. Georges, Navneet S. Majhail
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:845-854
Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing d
Publikováno v:
Neuroimmunology ISBN: 9783030618827
Multiple sclerosis (MS) is a heterogeneous immune-mediated disease that involves demyelination with inflammation in the central nervous system (CNS), as well as a neurodegenerative component. The natural history of the disease has changed favorably o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5866f3f4a385353303af1c15d9ac7f7d
https://doi.org/10.1007/978-3-030-61883-4_7
https://doi.org/10.1007/978-3-030-61883-4_7
Autor:
Robert J. Fox, Laura E. Baldassari
Publikováno v:
Drugs. 78:1549-1566
Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting disease, many transition to secondary progressive disease (SPMS) over time. This transition is thought to be related to neurodegenerative processes incre
Publikováno v:
Multiple Sclerosis Journal. 24:1347-1355
Background: The Expanded Disability Status Scale (EDSS) is the standard measure of disability in multiple sclerosis clinical trials. The EDSS has limited application in the clinical setting due to required completion time and scoring complexity. Syst
Autor:
Laura E. Baldassari, John W. Rose
Publikováno v:
Neurotherapeutics. 14:842-858
Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple mechanisms, including reduction of IL-2-mediated lymphocyte activation
Publikováno v:
Neurology: Clinical Practice. 8:e12-e14
A 53-year-old man with an 18-year history of multiple sclerosis (MS) was treated with natalizumab for 7 years. Two years prior to presentation, natalizumab treatment interval was increased to every 6 weeks in attempt to reduce the risk of PML. Medica
Autor:
Daniel Ontaneda, Kunio Nakamura, Jenny Feng, Laura E. Baldassari, Robert A. Bermel, Elizabeth Fisher, Kenneth Earl Sakaie, Sarah M. Planchon, Jeffrey A. Cohen
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple scl
Autor:
Daniel Ontaneda, Kunio Nakamura, Stephen M. Rao, Gabrielle Macaron, Jeffrey A. Cohen, Marisa P. McGinley, Stephen E. Jones, Brandon P Moss, Hong Li, Laura E. Baldassari, Deborah M. Miller, Robert A. Bermel, Devon S. Conway
Publikováno v:
European journal of neurologyReferences. 27(7)
BACKGROUND AND PURPOSE To analyze the relationship between cognitive processing speed, patient-reported outcome measures (PROMs), employment and magnetic resonance imaging (MRI) metrics in a large multiple sclerosis cohort. METHODS Cross-sectional cl